Tags

Type your tag names separated by a space and hit enter

[Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents].
Ugeskr Laeger 2003; 165(17):1755-9UL

Abstract

INTRODUCTION

Continuous intrathecal baclofen has been used over the past years especially in adult patients with spasticity of spinal origin. Children and young adults with severe spasticity and dystonia of cerebral origin are difficult to treat in spite of optimal systemic antispasmotic therapy with baclofen, tizanidine, dantrolene and/or diazepam. Intrathecal baclofen has therefore been applied in a group of young patients.

MATERIAL AND METHODS

Eight children and young adults from East Denmark with spasticity and 12 with dystonia aged 3-18 years (median 10.9 years) were tested, operated and treated with continuous intrathecal baclofen for a period of 2-64 months (median 22.2 months). Registration of efficacy, fillings, adjustments of baclofen and other therapies were performed in an out patient setting since 1995.

RESULTS

Spasticity in lower extremities was reduced from Ashworth score 3.5-4.5 (median 4.2) to Ashworth score 2.5-4.0 (median 2.9; p < 0.001) during infusion with baclofen 5-33 micrograms/kg/24 hours (median 19 micrograms/kg/24 hours). The infusion catheter tip was placed at levels Th1-Th12 (median Th7.5). Peroral baclofen was reduced from an average of 5.0 to 0.44 mg/kg/24 hours, tizanidine from 0.4 to 0.1 mg/kg/24 hours, and dantrolene from 4.0 to 0.4 mg/kg/24 hours. After initial adjustments successively increased dosages of average 0.46 microgram/kg/month were needed to maintain the same level of efficacy. In questionnaires parents or guardians rated less spasticity in lower extremities in 15 out of 19 patients, and less pain in 13 out of 19 patients.

CONCLUSION

Continuous intrathecal baclofen was effective in treating severe spasticity and dystonia of cerebral origin with major effect on muscles of the lower extremities, pelvis, and back and in particular opisthotonus was relieved. Efficacy on upper extremities was far less pronounced.

Authors+Show Affiliations

Neurocentret, Neurokirurgisk Afdeling, H:S Rigshopitalet, Juliane Marie Centret, Paediatrisk Klinik I. niels.illum@ouh.fyns-amt.dk

Pub Type(s)

English Abstract
Journal Article

Language

dan

PubMed ID

12768902

Citation

Illum, Niels Ove, et al. "[Intrathecal Baclofen in the Treatment of Severe Spastic Tetraplegia and Dystonia in Children and Adolescents]." Ugeskrift for Laeger, vol. 165, no. 17, 2003, pp. 1755-9.
Illum NO, Hansen FJ, Fischer C, et al. [Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents]. Ugeskr Laeg. 2003;165(17):1755-9.
Illum, N. O., Hansen, F. J., Fischer, C., Uldall, P. V., & Nielsen, O. A. (2003). [Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents]. Ugeskrift for Laeger, 165(17), pp. 1755-9.
Illum NO, et al. [Intrathecal Baclofen in the Treatment of Severe Spastic Tetraplegia and Dystonia in Children and Adolescents]. Ugeskr Laeg. 2003 Apr 21;165(17):1755-9. PubMed PMID: 12768902.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents]. AU - Illum,Niels Ove, AU - Hansen,Flemming Juul, AU - Fischer,Claudia, AU - Uldall,Peter V, AU - Nielsen,Ole Amtoft, PY - 2003/5/29/pubmed PY - 2003/6/13/medline PY - 2003/5/29/entrez SP - 1755 EP - 9 JF - Ugeskrift for laeger JO - Ugeskr. Laeg. VL - 165 IS - 17 N2 - INTRODUCTION: Continuous intrathecal baclofen has been used over the past years especially in adult patients with spasticity of spinal origin. Children and young adults with severe spasticity and dystonia of cerebral origin are difficult to treat in spite of optimal systemic antispasmotic therapy with baclofen, tizanidine, dantrolene and/or diazepam. Intrathecal baclofen has therefore been applied in a group of young patients. MATERIAL AND METHODS: Eight children and young adults from East Denmark with spasticity and 12 with dystonia aged 3-18 years (median 10.9 years) were tested, operated and treated with continuous intrathecal baclofen for a period of 2-64 months (median 22.2 months). Registration of efficacy, fillings, adjustments of baclofen and other therapies were performed in an out patient setting since 1995. RESULTS: Spasticity in lower extremities was reduced from Ashworth score 3.5-4.5 (median 4.2) to Ashworth score 2.5-4.0 (median 2.9; p < 0.001) during infusion with baclofen 5-33 micrograms/kg/24 hours (median 19 micrograms/kg/24 hours). The infusion catheter tip was placed at levels Th1-Th12 (median Th7.5). Peroral baclofen was reduced from an average of 5.0 to 0.44 mg/kg/24 hours, tizanidine from 0.4 to 0.1 mg/kg/24 hours, and dantrolene from 4.0 to 0.4 mg/kg/24 hours. After initial adjustments successively increased dosages of average 0.46 microgram/kg/month were needed to maintain the same level of efficacy. In questionnaires parents or guardians rated less spasticity in lower extremities in 15 out of 19 patients, and less pain in 13 out of 19 patients. CONCLUSION: Continuous intrathecal baclofen was effective in treating severe spasticity and dystonia of cerebral origin with major effect on muscles of the lower extremities, pelvis, and back and in particular opisthotonus was relieved. Efficacy on upper extremities was far less pronounced. SN - 0041-5782 UR - https://www.unboundmedicine.com/medline/citation/12768902/[Intrathecal_baclofen_in_the_treatment_of_severe_spastic_tetraplegia_and_dystonia_in_children_and_adolescents]_ L2 - http://www.diseaseinfosearch.org/result/2405 DB - PRIME DP - Unbound Medicine ER -